Attendance doubled in 2015 to welcome more that 75 leading CDx organisations to share valuable clinical and commercial insight into the co-development of drug-CDx combinations, including Pfizer, Novartis, Bayer, Merck, Boehringer Ingelheim, Sanofi to name a few.
There are possibly too many highlights from World CDx 2015, but here are a few talks that got rave reviews:
Rest assured World CDx Europe will be back bigger and better than ever in order to drive forward CDx collaborations between senior level pharma, biotech, diagnostic, technology & CRO stakeholders.
Joachim ReischlHead, Global Biomarker Strategy & Development Bayer
Richard BullerVice President, Oncology Clinical Development Pfizer
Maria OrrExecutive Director, Personalised Healthcare & Biomarkers AstraZeneca
Klaus LindpaintnerChief Scientific Officer Thermo Fisher Scientific
“This was a very useful meeting and I would recommend it highly. I liked the ability to share experiences and compare notes with others on the pharma & Dx industries. Very educational overall” Pfizer
“Expertise from thought leaders is rarely so freely given, or as earnestly debated.” CHI Center for Translational Research
“Excellent networking opportunities. Kudos on the attendee list” Sonia Kumar, CDx Program Manager, Leica Biosystems